Dr. Kamat is the Chief Executive Officer of Kamat Pharmatech. Dr. Kamat founded Kamat Pharmatech in 2013 after 27 years of working highly technical roles in pharmaceutical companies, most notably as Director of Manufacturing Technology of Sterile/Biological products at Bristol Myers Squibb.

Dr. Kamat is a recognized expert in the fields of lyophilization, nano-suspension technology, aseptic technology, and other sterile manufacturing processes. Following is a list of some products that Dr. Kamat was involved in development/launch/support:

• Biologicals: Yervoy, Nulojix IV, Orencia SC and IV, Erbitux, Remicade, Repro
• Small molecules: Ixempra, Tequin, Ketorolac, and Acyclovir
• Cytotoxics: Taxol, BicNu, Cytoxan, Carboplatin, Doxorubicin, Mutamycin, Etopophos
• Unique: Kenalog: Steroidal IM suspension product

Dr. Kamat serves as a registered pharmacist in the States of New Jersey and Pennsylvania.

Dr. Kamat also serves as a course director for "Lyophilization Technology" by CfPA in the US, Europe, and the rest of the world.